Возбуждённые: таинственная история эндокринологии. Властные гормоны, которые контролируют всю нашу жизнь (и даже больше)

11. N. E. Rance and W. S. Young III, “Hypertrophy and Increased Gene Expression of Neurons Containing Neurokinin-B and Substance-P Messenger Ribonucleic Acids in the Hypothalami of Postmenopausal Women,” Endocrinology 128, no. 5 (1991): 2239–2247. Обзор исследований Рэнс см. в статье Ty William Abel and Naomi Ellen Rance, “Stereologic Study of the Hypothalamic Infundibular Nucleus in Young and Older Women,” Journal of Comparative Neurology 424, no. 4 (2000): 679–688.

12. Channa Jayasena, “Neurokinin B Administration Induces Hot Flushes in Women,” Scientifi c Reports 5, no. 8466 (2015).

13. Julia K. Prague et al., “Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial,” Lancet 389, no. 10081 (May 2017): 1809–1820. Articles on the potential new nonhormone drug include Megan Cully, “Neurokinin 3 Receptor Antagonist Revival Heats Up with Astellas Acquisition,” Nature Reviews Drug Discovery 16, no. 6 (2017): 377.

14. Heyman et al., “Alzheimer’s Disease”; V. W. Henderson et al., “Estrogen Replacement Therapy in Older Women: Comparisons Between Alzheimer’s Disease Cases and Nondemented Control Subjects,” Archives of Neurology 51, no. 9 (1994): 896–900; Tang et al., “Effect of Oestrogen.”

15. Randall S. Stafford et al., “The Declining Impact of Race and Insurance Status on Hormone Replacement Therapy,” Menopause 5, no. 3 (1998): 140–144; Watkins, The Estrogen Elixir.

16. Kate M. Brett and Jennifer H. Madans, “Differences in Use of Postmenopausal Hormone Replacement Therapy by Black and White Women,” Menopause 4, no. 2 (1997): 66–76.

17. Stafford et al., “The Declining Impact of Race and Insurance Status.”

18. Krieger et al., “Hormone Replacement Therapy, Cancer, Controversies, and Women’s Health.”

19. Robert Wilson, Feminine Forever (New York: Pocket Books, 1968), 52.

20. Krieger et al., “Hormone Replacement Therapy, Cancer, Controversies, and Women’s Health”; Judith Houck, Hot and Bothered: Women, Medicine, and Menopause in Modern America (Cambridge, MA: Harvard University Press, 2006).

21. Krieger et al., “Hormone Replacement Therapy, Cancer, Controversies, and Women’s Health.”

22. The Writing Group for the PEPI Trial, “Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial.” Journal of the American Medical Association 273, no. 3 (1995): 199–208.

23. Meir J. Stampfer et al., “Postmenopausal Estrogen Therapy and Cardiovascular Disease,” New England Journal of Medicine 325, no. 11 (1991): 756–762.

24. Watkins, The Estrogen Elixir.

25. R. D. Langer, “The Evidence Base for HRT: What Can We Believe?” Climacteric 20, no. 2 (2017): 91–96.

26. Доктор Джоанн Мэнсон, интервью автора.

27. Krieger et al., “Hormone Replacement Therapy, Cancer, Controversies, and Women’s Health.”

28. J. E. Manson et al. for the WHI Investigators, “Menopausal Hormone Therapy and Long-Term All-Cause and Cause-Specifi c Mortality: The Women’s Health Initiative Randomized Trials,” Journal of the American Medical Association 318, no. 10 (2017): 927–938.

29. Lisa Rapaport, “Menopause Hormone Not Linked to Premature Death,” Reuters Health, September 12, 2017.

30. Nanette Santoro et al., “Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientifi c Statement,” Journal of Clinical Endocrinology and Metabolism 101, no. 4 (2016): 1318–1343.

31. Cathr yn Jakobson Ramin, “The Hormone Hoax Thousands Fall For,” More, October 2013, 134–144, 156.

32. North American Menopause Society, “The 2017 Hormone Therapy Position Statement of the North American Menopause Society,” Menopause 24, no. 7 (2017): 728–753.

Глава двенадцатая. Торговцы тестостероном